newsfilter
← Latest News
Business Wire·

First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease

Vamifeport (VIT-2763) is the first oral ferroportin inhibitor investigated for treatment of diseases with ineffective production of red blood cells and iron overload such as sickle cell disease (SCD) SCD is a rare blood disorder with currently lim